PARP inhibitor YCH1899 activates type I interferon signaling and synergizes with STING agonists in BRCA-proficient tumors
Poly(ADP-ribose) polymerase (PARP) inhibitors are highly effective in BRCA-deficient tumors, yet their therapeutic benefit in BRCA-proficient cancers remains limited. Here, we demonstrate that YCH1899, a next-generation, resistance-overcoming PARP inhibitor, elicits significantly stronger type I interferon signaling th...